Intellia Therapeutics, Inc.

Ownership Transactions Reported by 20 Insiders

Symbol
NTLA on Nasdaq
Industry
In Vitro & In Vivo Diagnostic Substances
Location
40 Erie Street, Suite 130, Cambridge, MA

Insiders trading volume in the past year

Intellia Therapeutics, Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
John M. Leonard President and CEO, Director $10.2M -$327K -3.1% Mar 1, 2025
Glenn Goddard EVP, Chief Financial Officer $2.11M Mar 1, 2024
Birgit C. Schultes EVP, Chief Scientific Officer $1.83M -$539 -0.03% Oct 1, 2025
Edward J. Dulac III EVP, Chief Financial Officer $1.49M -$105K -6.57% Jul 23, 2025
William Chase Director $1.35M +$1M +288% Aug 20, 2025
David Lebwohl EVP, Chief Medical Officer $1.18M -$116K -9% Mar 1, 2025
James Basta EVP, General Counsel $1.01M -$109K -9.8% Mar 1, 2025
Michael P. Dube VP, Chief Accounting Officer $961K -$74.1K -7.17% Oct 1, 2025
Laura Sepp-Lorenzino EVP, Chief Scientific Officer $943K -$109K -10.4% Jan 3, 2025
Eliana Clark EVP, Chief Technical Officer $937K -$113K -10.8% Jul 1, 2025
Derek Hicks EVP, Chief Business Officer $729K -$79.2K -9.8% Jan 3, 2025
Fred E. Cohen Director $478K Jun 11, 2025
Caroline Dorsa Director $373K Jun 14, 2022
John F. Crowley Director $344K Jun 14, 2023
Georgia Keresty Director $265K Jun 11, 2025
Muna Bhanji Director $226K -$4.9K -2.12% Jun 11, 2025
Jesse Goodman Director $225K -$29.1K -11.4% Jun 30, 2025
Frank Verwiel Director $216K Jun 11, 2025
Formela Jean Francois Director $214K Jun 14, 2022
Brian Goff Director $195K Jun 11, 2025

Recent Insider Transactions by Companies or Individuals for Intellia Therapeutics, Inc.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.